Stakeholder Perspectives on the Use of Telehealth to Support Deprescribing for Older Patients Transitioning From the Hospital to Home Health Care Authors: Jinjiao Wang, Jenny Y. Shen, Fang Yu, Sandra F. Simmons, Amanda S. Mixon, Kobi Nathan, Marian S. Moskow, Judith D. Brasch, Sally A. Norton, Kathi L. Heffner, Yun Jiang, Sudha Seshadri, Neela Patel, Lixin Song, Joseph A. Zorek, Christine Lam, Thomas V. Caprio Published: 2026 ABSTRACT ABSTRACTBackgroundMultimorbidity affects most older adults in home health care (HHC), leading to inappropriate polypharmacy and increased risks for adverse outcomes. While deprescribing can mitigate these risks, fragmented communication during hospital‐to‐home transitions remains a major barrier. This study explored stakeholder perspectives on using telehealth to facilitate deprescribing for older adults with multimorbidity while receiving post‐acute HHC.MethodsWe conducted semi‐structured interviews with 44 stakeholders across 12 U.S. states, including 14 HHC patients and 30 clinicians (physicians, nurse practitioners, pharmacists, and HHC nurses). Guided by the socioecological model of deprescribing, interviews explored factors across individual, interpersonal, organizational, and societal levels associated with telehealth use in deprescribing. Analysis followed a phased, iterative approach with independent double‐coding and interprofessional team consensus to ensure credibility.ResultsFindings categorized telehealth as a promising tool to align medications with the “4Ms” (Medications, Mentation, Mobility, and What Matters) through goal‐concordant deprescribing. At the individual level, stakeholders noted that telehealth readiness depended on patient cognition and digital literacy. At the interpersonal level, telehealth facilitated real‐time multidisciplinary “virtual huddles” that reduced communication delays but could occasionally overwhelm patients and may be logistically challenging to schedule. Organizational barriers included reimbursement constraints and complex synchronous scheduling. Societal factors include equitable access for rural or low‐income populations, populations who may benefit the most from telehealth‐enabled deprescribing due to challenges in accessing care. Stakeholders emphasized a hybrid approach which pairs virtual prescriber consultation with in‐home support of a clinician to provide context and assist with implementation for patient‐centered deprescribing.ConclusionsTelehealth can support goal‐concordant deprescribing during post‐acute care transitions in HHC. A hybrid model, one that combines remote prescriber consultations with in‐home clinician support, is the preferred approach to bridge coordination gaps. To maximize impact, future efforts are needed to improve reimbursement, infrastructure, and scheduling to integrate telehealth into routine deprescribing workflows. Introduction Multimorbidity affects up to 87% of older adults and often leads to complex medication regimens with potentially inappropriate medications (PIMs) that may be harmful or unnecessary as health status and goals evolve [1, 2, 3, 4]. In the Age‐Friendly “4Ms” model, hospital‐to‐home transitions are high‐risk periods where medication changes can conflict with Mentation, Mobility, and What Matters [5, 6, 7, 8, 9]. While deprescribing reduces harms associated with PIM use and improves cognitive and physical function [10, 11], its implementation remains difficult during post‐acute transitions [12]. Home health care (HHC) serves 40%–70% older adults post‐hospitalization, offering a strategic setting for deprescribing [8, 13, 14, 15]. Successful hospital‐to‐home transition is often derailed by fragmented communication between patients, prescribers, HHC clinicians, and pharmacists [16], representing a primary barrier to deprescribing [17]. Telehealth, including telephone calls, remote monitoring, messaging in electronic health records (EHR), and audio/video visits, is a potential solution to bridge coordination gaps [18, 19, 20]. Telehealth was initially used in HHC for remote monitoring of chronic conditions [18], and expanded rapidly during the COVID‐19 pandemic to include more delivery modalities, for example, video visits [21, 22]. This evolution presents an opportunity to leverage telehealth to facilitate complex clinical conversations, such as the communication, collaboration and shared decision‐making for deprescribing in post‐acute care transitions [22, 23, 24]. In this exploratory qualitative study, we gathered perspectives of key stakeholders, including patients, prescribers, pharmacists, and HHC clinicians, regarding the potential role of telehealth in deprescribing for older patients receiving post‐acute HHC. By applying a socioecological deprescribing model, we sought to identify how telehealth can be intentionally designed to facilitate goal‐concordant deprescribing and optimize medication safety for older adults during the hospital‐to‐home transition. Methods We conducted individual, semi‐structured, qualitative interviews with stakeholders involved in deprescribing older patients receiving post‐acute HHC. The University of Rochester Institutional Review Board approved this study (IRB #00006218). Conceptual Model This study was guided by the socioecological deprescribing model for patients with multiple prescribers [25], which organizes deprescribing barriers and facilitators across individual (patient capacity), interpersonal (care team, caregiver), organizational (reimbursement, infrastructure), and societal levels (accessibility, policies). This model guided the interview guide development and provided a deductive framework for coding analysis. Sample We employed purposeful sampling to recruit the following stakeholders: (1) recently hospitalized older patients with multimorbidity and polypharmacy receiving HHC post‐discharge; (2) clinicians involved in deprescribing during the hospital‐to‐home transition, including primary care providers (PCPs), hospitalists, and nurse practitioners working in post‐acute skilled nursing facilities; and (3) HHC registered nurses. This sampling strategy aimed at capturing perspectives from stakeholders who play distinct but complementary roles in deprescribing during care transitions. All stakeholders were English‐speaking and capable of self‐consent. Patient eligibility included: (a) ≥ 65 years old; (b) having a hospital discharge to HHC within the past 24 months; (c) taking ≥ five prescription medications daily; and (d) not in hospice. This timeframe was selected to ensure a sufficient pool of patients with recent hospital‐to‐home transition experience. Clinician eligibility required ≥ 12 months of experience in their respective fields (acute, post‐acute, primary care, or HHC). Recruitment Patients, prescribers, and pharmacists were recruited locally within existing care networks in New York. To accommodate the well‐documented geographic variability in HHC delivery [26], HHC nurses were recruited nationally through collaboration with National Alliance for Care at Home. To enhance diverse representation, we utilized a multi‐stage recruitment strategy. Patients (Group 1): We identified patients from existing research‐consented registries, sorting by zip code, race/ethnicity to enhance participation of under‐represented populations in HHC research, for example, Hispanics, African Americans, and individuals with low income, lack of internet access, or living in rural regions [27, 28]. Clinicians (Groups 2 and 3): We targeted clinical roles across the care continuum (acute, post‐acute, and primary care). Local prescribers and pharmacists were recruited via study flyers to healthcare partnerships. HHC nurses were recruited nationally through NAHC email list, resulting in participants from 12 states. Data Collection Informed by the socioecological deprescribing model [25], we developed semi‐structured interview guides tailored to each stakeholder group. Guides solicited stakeholders' experiences with telehealth and deprescribing and were iteratively refined after the first 2–3 interviews in each group to improve clarity and incorporate emerging themes [25, 29, 30]. All participants' data were included. Trained staff conducted individual interviews via telephone or HIPPA‐compliant video conferencing, each lasting 60–90 min. Interviews were audio‐recorded and supplemented with notes. Data collection continued until thematic saturation was achieved within each group, that is, when consecutive interviews yielded no new theme. Codebook Development and Data Analyses Audio‐recorded interviews were transcribed verbatim and managed in Atlas.ti. We used the socioecological deprescribing model to guide a phased analysis [31]: (1) Open coding to identify and categorize novel ideas, and deprescribing concepts in the guiding model to develop a coding framework that integrated both emergent insights and predefined topics; (2) Coding all transcripts using this framework; and (3) Cross‐group comparisons to identify patterns, variations, barriers, and facilitators across stakeholders [32, 33, 34]. To ensure credibility, an interprofessional coding team (PI, study nurse, PhD student, and qualitative researcher) employed a multi‐step analytic process to mitigate subjective bias [35]. All initial transcripts (n = 23) were independently double‐coded by at least two team members to ensure triangulation of findings. The team held regular meetings to compare coding, resolve discrepancies via consensus, and ensure analytical depth while mitigating individual bias. Results Stakeholder Characteristics (Table 1) TABLE 1Demographic characteristics by stakeholder group.Patients (n = 14)CliniciansPrescribers and pharmacists a (n = 15)Home health care nurses (n = 15)Average age, mean (SD)70.9 (6.11)36.3 (4.85)46.6 (12.20)Female, %55.6%80.0%90.9%Race and ethnicity, %Non‐Hispanic White77.7%80%100%Other22.3%20%0Education, %High school graduate33.3%00College22.2%045.5%Graduate/professional school44.4%10%45.5%Doctorate degree090%9.1%Married, %55.6%N/AN/ALiving arrangement, %Living alone33.3%N/AN/ALiving with others66.7%In congregate residential facilities0Years of experience in current role, mean (SD)N/A6.1 (3.41)10.8 (12.25) a For the group of “prescribers and pharmacists,” prescribers include primary care providers, hospitalists, post‐acute care nurse practitioners, and pharmacists; demographic characteristics are presented in aggregate for this group. Demographic characteristics by stakeholder group. For the group of “prescribers and pharmacists,” prescribers include primary care providers, hospitalists, post‐acute care nurse practitioners, and pharmacists; demographic characteristics are presented in aggregate for this group. The sample included 14 patients (average age 71 ± 6.11 years), 15 prescribers and pharmacists (average age 36 ± 4.85 years), and 15 HHC nurses (average age 47 ± 12.2 years). Most stakeholders were non‐Hispanic White and female. On average, prescribers and pharmacists had 6.2 years of experience in their current roles, while HHC nurses had 8.2 years. Among the patients, three identified as African Americans and reported not having Internet access in their homes. All clinicians reported experience delivering care via telehealth, and over half patients reported having used telehealth to receive care. Stakeholders described using various telehealth modalities, including remote patient monitoring, patient messaging via EHR portals and real‐time audio or video visits. Although we defined telehealth broadly, participants' examples focused mainly on synchronous audio/video visits. Findings are organized below according to the socioecological model of deprescribing (Figure 1), with quotes shared in Table 2. Socioecological model of telehealth use in deprescribing for patients receiving home health care. TABLE 2Themes and illustrative quotes organized by the socioecological model of deprescribing.ThemeStakeholder groupIllustrative quoteIndividual level: Patient capacity and readiness for telehealth‐supported medication optimizationPatient health and digital literacy, cognitive capacity shape telehealth feasibility for medication reviewPrescriber“Depending on the patient, they're actually able to tell us, ‘Okay, here's what I'm taking. This is what I have in my medicine cabinet,’ and then we can go from there. Unfortunately, there are patients who cannot say that and even describing the color of a medication in their pill bottle is very challenging. And so, in those cases, I have to bring the patient on for an on‐site visit to try to do med recs.”HHC Nurse“Some of the disadvantages is that a lot of my patients are older. They're not really versed in technology so I had to go there and set it up. There was one time where I was unable to be there, we had to get another nurse to go out and do it for them, who didn't know the patient as well.”HHC Nurse“People are becoming much more savvy. I think COVID really helped with that. Because 89‐year‐old grandmas couldn't see their grandchildren in person. So, now they're doing video, and it's basically the same process. I think people don't give our elderly patients enough credit. I think they can learn how to do it.”Patient varied willingness to discuss medication and deprescribing via telehealthPatient“I don't see why not. I mean, it's not all that different than visiting the doctor in person. Obviously, like changing the dose on my thyroid medication, that requires blood work, so you can't do blood work over Zoom. But I don't see why you wouldn't be able to have that conversation with your health care provider.”Patient“I have had Zoom calls, and I have had just normal telephone calls. To be honest, I much prefer face‐to‐face, in person … when you're talkin’ to somebody on the phone, you don't have that connection, and even with the Zoom, you don't have that connection because you don't appreciate each other's body language.”Dependence on caregiver for technology navigationPatient/Caregiver“My husband is 87. He has COPD, he has some renal issues. He has peripheral vascular disease. We have met with a couple of his doctors by Zoom, it's been very helpful, very convenient … I am present for his visits because he is not comfortable with the technology.”Patients may lack access to devices or InternetPatient“My phone doesn't have video, so I haven't done [video visit].”Interpersonal level: Team‐based communication and shared decision‐making for deprescribingCommunication and real‐time, multidisciplinary medication decisionsHHC Nurse“If we had a system where we could just directly talk with the provider or talk with multiple providers dealing with one patient, I think that would be really helpful … ‘cause sometimes I feel like calling, a lot of it gets lost in the mix. You're playing phone tag.”HHC Nurse“I only really had communication via the Zoom with the provider and the pharmacist. I felt, during the Zoom, that we could fix a lot of problems right then and there, if it were discontinuing a medication of some sort or adding something we felt they needed. I thought it was most helpful having the provider there, who can actually say, okay, yep, stop taking that, or okay, yep, we're gonna up that a little bit, and the pharmacist there, also verifying yes, that's okay, that works, doing a little education with that.”HHC Nurse“It's one line of communication. It's not like telephone where they may say one thing and then by the time it gets to you, it's slightly altered—everyone's hearing the same thing at the same time, so we're all on board with the same idea.”Prompt for providers to reconsider medication necessityPrescriber“In terms of deprescribing, it would kinda help almost facilitate a conversation with, ‘Well, what's this for? And are you taking—’ ‘I don't know what it's for.’ It might actually kind of force me as a provider to be like, ‘Oh, yeah. Why are you on this med?’ ‘Cause we all think about deprescribing, but it's not something that we always actively do, especially when you're pressed with other acute complaints.”HHC nurse in‐home presence during virtual visits provides contextual medication insights and facilitates accurate medication reconciliationHHC Nurse“If I'm not there, the prescriber misses a lot—what the house looks like, how the meds are stored, how the patient is really doing.”Prescriber“I've had a couple instances where I've actually connected with a home nurse for a particular patient that—tryin’ to figure out what medications they have or not have at home. Very helpful, especially when they're actually in the patient's home. We were able to get a good solid med list. So absolutely very helpful.”HHC Nurse“If you're gonna do virtual visits to supplement home care visits, then I think that allows you then to have them put the pill up next to the screen. They can go, ‘This is what I'm taking, right?’ And so you can say, ‘Well, let me see the pillbox.’“Caregiver engagement via telehealth, including out‐of‐state familyHHC Nurse“Most of the time those are not the people we're doing the telehealth visit on ‘cause those people have somebody to take them to the visit. It's usually the people that don't have anybody. Their kids all live out of state. We have conference‐called in kids from out of state that are very involved in their care.”Psychological burden in team‐based telehealth discussionsPatient“It kind of felt like they were ganging up on us. Everyone's on the screen, telling me what to do with my meds—it was a bit much.”Organizational level: Reimbursement, scheduling, and workforce barriersHHC telehealth reimbursement and investmentHHC Nurse/Administrator“Home health is ultimately a business. Virtual visits don't count as reimbursable visits, so it's hard to justify the nurse's time if it's not going to be paid for.”HHC Nurse“The payment side of things has not caught up on the home health. We are able to use a telehealth visit, and it counts towards part of our payment but not in a significant manner to where we would use it very many times.”HHC Nurse/Administrator“One hospitalization would cost us $50,000 sometimes, and a GrandPad costs us $300–$400, and we could possibly keep a patient out of the hospital by having one of those. It's well worth the investment.”Scheduling of team‐based telehealth discussionsPrescriber“It's hard enough to schedule a visit with the patient, let alone with their caregiver, the home health nurse, and a pharmacist who might be based somewhere else entirely.”Pharmacist and specialist availabilityHHC Nurse“We have [done telehealth] with providers. And that's gone very well. We haven't with pharmacy.”Need for dedicated care coordinatorPrescriber“Care coordinators or health promoters, social workers that do work as care coordinators—I think they do a lot of bridging those gaps. I think they're the ones that come to mind, initially, to help coordinate and facilitate these kinds of visits and practices.”HHC Nurse“Someone at [the facility] could coordinate, a new position. Actually, that would probably be the most ideal ‘cause everyone's so busy as it is.”Continuity of care disruption if need to use a substitute home health care nurseHHC Nurse“Some of the disadvantages is that a lot of my patients are older. They're not really versed in technology so I had to go there and set it up. There was one time where I was unable to be there. We had to get another nurse to go out and do it for them, who didn't know the patient as well.”Societal level: The digital divide and equitable accessAddressing mobility or transportation barriers by eliminating travelPatient“We have met with doctors by Zoom. It's been very helpful. I don't live in the city, and it's a hike to go to the doctors.”HHC Nurse“From our standpoint, where telehealth becomes huge is that initial visit, of that follow‐up visit after the hospital that can happen when the patient doesn't need to leave the home. I think that's a big thing.”Extension of clinical reach beyond episodic visitsHHC Nurse“If it was up to me, every high‐risk patient would have like an iPad in their home where they could—so it's 10:00 at night and they're calling the nurse saying, ‘I don't understand how to do this, or I have some questions about this.’ We can connect via video.”Infrastructure and resources needed for telehealth accessHHC Nurse“Specifically to our population in rural [State], we have an aging population. And it is difficult sometimes for them to use technology. We also, because we are rural, have several areas that may not have internet connections or the availability for internet, and that's a challenge.”HHC Nurse“As far as the internet availability … when we get into some of my sites in [State], it is actually considered frontier—so there's no cell service, there's no internet.”Digital dividePrescriber“Telehealth is a tool. If done well, it can promote health for all. If not, it will just continue to worsen things for those who are least supported.”HHC Nurse“Most of the time it's our people that really don't have anybody that we're using those telehealth calls on, and we're assisting with.”Preferred model: Hybrid team‐based approachVideo preferred over audio for clinical assessmentPatient“[Video call] is much better than phone, because you get an awful lot of information about how they look, and how they move, and all that sorta stuff, which you can't get over the phone.”In‐home clinician essential for hands‐on assessmentHHC Nurse“If you can do it at the same time as home health—and when I say home health, I mean a home health registered nurse or an LVN in the home—is key to have that person in the home to be able to help you facilitate telehealth.”Hybrid model acknowledged as time‐intensiveHHC Nurse“Scheduling a team‐based video visit will be difficult and can be time‐consuming if all need to be present … very helpful, although it is time‐consuming.”In‐person assessment irreplaceable for certain tasksPatient“A physical exam, a hands‐on assessment … even something as simple as taking blood pressure. There is no substitute for human‐to‐human contact.”Initial in‐person visit builds rapport for future telehealth successHHC Nurse“I always like to see ‘em in person the very first time. That's very helpful for a successful telehealth visit in the future.” Themes and illustrative quotes organized by the socioecological model of deprescribing. Individual Level: Patient Capacity and Readiness Stakeholders described considerable variation in patients' ability to participate in telehealth‐facilitated medication and deprescribing discussions. Patients with adequate health literacy and cognitive function were viewed as well‐suited for these virtual discussions. One prescriber noted that some patients can confidently report what they are taking: “Depending on the patient, they're actually able to tell us, Here's what I'm taking. This is what I have in my medicine cabinet, and then we can go from there.” Patients also recognized that many components of a deprescribing conversation could occur virtually. As one patient shared: “You can talk through everything, but if they need to take your vitals or do blood work, that still needs to be in person.” However, stakeholders consistently noted that patients with cognitive impairment or low health literacy faced substantial barriers to meaningful telehealth participation. The same prescriber explained: “Unfortunately, there are patients who cannot say that [name of a medication] and even describing the color of a medication in their pill bottle is very challenging. In those cases, I have to bring the patient on for an on‐site visit to try to do med recs.” Several HHC nurses described patients as dependent on a nurse or caregiver to navigate the technology, and one patient who also served as a caregiver shared: “I am present for my husband's tele‐visits because he is not comfortable with the technology.” Patients who lacked Internet access were excluded; as one patient stated: “My phone doesn't have video, so I haven't done it.” Together, these individual‐level factors suggest that readiness for telehealth‐enabled deprescribing must be assessed on a patient‐by‐patient basis, with particular attention to cognitive status, health literacy, caregiver support, and digital access. Interpersonal Level: Team‐Based Communication and Shared Decision‐Making The most distinctive finding was the potential for telehealth to facilitate real‐time multidisciplinary communication for deprescribing, though stakeholders noted such encounters were originally developed for patients with COVID after hospitalization, and are still rare in routine practice. One HHC nurse recalled a home visit during which she connected with the patient's PCP and a pharmacist via video conferencing, enabling immediate medication adjustments and assistance for the patient at home: “I thought it was most helpful having the provider there, who can actually say, okay, stop taking that, or we're gonna up that a little bit, and the pharmacist there, also verifying yes, that works, doing a little education with that.” This nurse further described the communication advantage: “It's one line of communication, not like telephone where they may say one thing and then by the time it gets to you, it's slightly altered. Everyone's hearing the same thing at the same time.” Prescribers also highlighted how telehealth could prompt deprescribing that might otherwise be deferred. One prescriber reflected: “Just seeing the patient in their home, even virtually, makes you rethink some of the meds—are they still necessary? Are they causing more harm than good?” Another prescriber described using telehealth for focused medication review: “When you're on the phone with the patient, I say, ‘Alright, take out your meds. Let's really go through this in depth’.” HHC nurses also noted that telehealth would reduce the “phone tag” delays if multidisciplinary visits were easier to coordinate: “If we had a system where we could just talk with the provider or multiple providers dealing with one patient, I think that would be really helpful.” Pharmacists' perspectives further emphasized the value of telehealth for team‐based medication optimization. As one pharmacist explained, “Home health nurses are the ones who are there with the patient … they can see if the patient is actually taking their medications and how they're taking them, and then call us so both the provider and I can weigh in.” However, stakeholders also cautioned that telehealth‐facilitated team visits could be psychologically overwhelming for some patients. One patient shared: “It kind of felt like they were ganging up on us. Everyone's on the screen, telling me what to do with my meds—it was a bit much.” HHC nurses emphasized the importance of the in‐home clinician's role during these encounters, not only for technical support but also for providing contextual insights that remote participants cannot observe. As one HHC nurse stated: “If I'm not there, the prescriber misses a lot—what the house looks like, how the meds are stored, how the patient is really doing.” This included the ability to review the home medication cabinet, identifying expired, duplicated, or already‐discontinued medications, as a practical extension of telehealth‐supported medication optimization and deprescribing. Caregiver involvement during telehealth visits emerged as an important interpersonal facilitator. HHC nurses described conference‐calling family members from out of state when patients requested their involvement, though they noted a paradox: “Most of the time it's our people that really don't have anybody that we're using those telehealth calls on, and we're assisting with.” Clinicians agreed that caregiver participation, whether in‐person or virtual, strengthened the quality of deprescribing conversations and ensured patients had support for understanding and implementing medication changes. Organizational Level: Reimbursement, Scheduling, and Workforce Barriers Stakeholders identified organizational factors that limit the use of telehealth in deprescribing. Reimbursement was the most frequently cited structural constraint. One HHC nurse (also an administrator) explained: “Home health is ultimately a business. Virtual visits don't count as reimbursable visits, so it's hard to justify the nurse's time if it's not paid for.” Another HHC nurse elaborated: “The payment side of things has not caught up on the home health. We are able to use a telehealth visit, and it counts towards part of our payment but not in a significant manner to where we would use it many times.” Some HHC agencies, however, recognized that the investment could be justified for high‐risk patients, as one HHC nurse/administrator noted that “one hospitalization would cost us $50,000 sometimes, a GrandPad costs us $300–$400, and we could possibly keep a patient out of the hospital by having one.” Scheduling synchronous team‐based telehealth sessions was described as logistically challenging and time‐consuming across all clinician groups. One prescriber explained: “It's hard enough to schedule a visit with the patient, let alone with their caregiver, the home health nurse, and a pharmacist who might be based somewhere else entirely.” HHC nurses noted that pharmacists and specialists were particularly difficult to include: “We have done (team‐based telehealth) with providers. We haven't with pharmacy.” Even when attempted, coordinating across multiple schedules required dedicated personnel. Stakeholders recommended creating a dedicated care coordination role to manage logistics, particularly by individuals who have access to the EHR systems used by the patient's prescribers. Continuity of care posed an additional organizational concern. Stakeholders noted that when the assigned HHC nurse was unavailable and a substitute unfamiliar with the patient conducted the home visit, the value of the telehealth encounter was diminished: “I had to go there and set it up. There was one time where I was unable to be there. We had to get another nurse to go out and do it for them, who didn't know the patient as well.” Societal Level: Equitable Access and the Digital Divide Across stakeholder groups, concerns about equitable access to telehealth‐supported deprescribing reflected broader societal‐level barriers. Stakeholders described a digital divide that disproportionately affected older adults in rural areas or with lower socioeconomic status. One HHC nurse working in a rural state shared: “We have an aging population. And it is difficult sometimes for them to use technology. We also, because we are rural, have several areas that may not have internet connections or the availability for internet.” In some frontier areas, neither cell service nor internet was available, rendering telehealth impossible. Stakeholders recognized that this inequity created a paradox: the patients who could benefit most from telehealth‐supported deprescribing, for example, those who are homebound, lack transportation, or have mobility limitations, often had the fewest resources to access it. While one PCP noted: “Some of my patients don't have cars. They'd have to lug all their meds in a cab or a bus, or walk to my office. That's just not feasible,” these same patients also often lack the devices, connectivity, or in‐home support necessary for virtual visits. Stakeholders underscored the need for equitable implementation, with one provider reflecting: “Telehealth is a tool. If done well, it can promote health for all. If not, it will just continue to worsen things for those who are least supported.” Several stakeholders noted that patients with complex needs, including heart failure, cognitive impairment, or low health literacy, may require in‐person care due to the limitations of current telehealth technologies. One patient expressed this tension: “There is no substitute for human‐to‐human contact.” Preferred Model: Hybrid Team‐Based Approach When asked about the ideal telehealth model for deprescribing support, most stakeholders endorsed a synchronous video consultation that includes the patient, caregiver (if applicable), a prescriber or pharmacist, and an in‐home clinician such as HHC nurse. The in‐home clinician's presence was considered essential to assess adherence, review the medication cabinet, identify adverse effects, and provide real‐time contextual information. As one patient shared: “Video is much better than phone, because you get an awful lot of information about how they look, and how they move, and all that sorta stuff, which you can't get over the phone.” Stakeholders acknowledged that this model requires substantial care coordination and adequate reimbursement to be sustainable. As one HHC nurse summarized: “Scheduling a team‐based video visit will be difficult and can be time‐consuming if all need to be present … very helpful, although it is time‐consuming.” Discussion This study extends prior work on telehealth and medication management by focusing specifically on deprescribing during hospital‐to‐home transitions in HHC and by integrating perspectives from patients, prescribers, pharmacists, and HHC nurses within a socioecological framework. Stakeholders viewed telehealth as promising for improving communication, care coordination, and medication review, but cited practical barriers in reimbursement, scheduling, and digital access. A hybrid model that combines virtual consultations with in‐home assessments by healthcare professionals emerged as the preferred approach, though it also has limitations. These findings expanded existing deprescribing conceptual models for older adults with multiple prescribers [25, 29, 30, 36], by highlighting challenges across individual, interpersonal, organizational, and societal levels that are unique to care transitions and homebound patients, and how telehealth can address them. Taken together, our findings highlight that telehealth is not a stand‐alone solution, but a tool whose impact depends on how well it aligns medications with the Age‐Friendly “4Ms” (Mentation, Mobility, and What Matters). At the patient level, our findings highlight that telehealth‐supported deprescribing is feasible mostly for those with sufficient digital access, cognitive capacity (Mentation), and caregiver support. This mirrors our results showing that readiness must be assessed on a patient‐by‐patient basis. Integrating “telehealth readiness” assessments into discharge planning ensures that virtual visits are targeted to patients who can meaningfully participate, while those with cognitive or literacy barriers receive prioritized in‐home support. At the interpersonal level, telehealth's distinctive contribution is its ability to bring patients, caregivers, HHC nurses, and prescribers into a shared conversation. These “virtual huddles” allow all parties to hear the same information simultaneously, fostering shared decision‐making that respects What Matters to the patient, thus overcoming the fragmented communication across care settings, a well‐documented barrier to deprescribing in care transitions [17, 25, 37]. However, the potential for patients to feel “ganged up on” suggests that these encounters should be used cautiously, best with clear selection criteria for the patients and defined roles for the in‐home clinician. At the organizational level, the lack of reimbursement for HHC virtual visits and limited EHR interoperability remain major barriers to implementation of telehealth‐based deprescribing. Our findings suggest that because telehealth encounters are not currently billable under CMS rules, this means that HHC agencies may have limited financial incentive to support the time, technology, and care coordination required for telehealth‐enabled deprescribing, even when such approaches may help prevent downstream adverse events or hospitalizations. Sustainable deprescribing will require payment models that treat HHC clinicians' telehealth work as billable clinical care and support telehealth infrastructure within value‐based arrangements, rather than adding uncompensated workload. Our findings underscore a paradox at the societal level. On the one hand, stakeholders recognized the potential for telehealth to improve access to medication management, particularly for older adults who are homebound, live alone, or lack transportation, as prior research suggested [38, 39]. However, the homebound patients who could benefit most from virtual medication optimization often face the greatest digital barriers. This digital divide, exacerbated by rurality and low socioeconomic status, suggests that telehealth must be implemented equitably to avoid widening existing disparities in medication safety. Findings extend prior studies on telehealth in medication management and deprescribing, which have largely focused on the personal and interpersonal levels. For instance, while pharmacist‐led telehealth interventions have achieved significant deprescribing feasibility and effectiveness [40, 41], our study adds critical nuance regarding implementational considerations at the organizational and societal levels. Stakeholders expressed a clear preference for a hybrid model, where virtual consultations with remote prescribers are paired with an in‐home clinician such as HHC nurse. This in‐home clinician provides critical context that remote participants cannot observe, such as assessing Mobility (e.g., fall risk) and Mentation (e.g., cognitive capacity) of the patient, and performing physical “medication cabinet” sweeps (Medication) to identify targets for deprescribing. The in‐home clinician can also help implement deprescribing and monitor for safety concerns. This hybrid model may be particularly effective at overcoming multi‐level barriers in telehealth‐enabled deprescribing for homebound patients, patients with cognitive impairment, functional challenges, limited health literacy, or those lacking reliable Internet who may struggle to engage meaningfully otherwise. By ensuring an in‐home clinician is physically present during virtual visits, teams can better manage patient needs, while allowing other members to contribute asynchronously as required. Our findings can inform future goal‐concordant medication optimization and deprescribing interventions. Effective models may require dedicated care coordination, flexible scheduling, and interoperable EHR that support shared documentation for the care team. To support the hybrid telehealth‐enabled deprescribing model emphasized by stakeholders, healthcare systems should invest in infrastructure that enables multidisciplinary care, such as asynchronous communication tools. Protecting clinician time for deprescribing may also yield downstream savings by preventing adverse drug events. Policy efforts should address reimbursement barriers by recognizing clinicians' participation in telehealth visits as billable services and ensuring universal digital accessibility to reduce disparities in care. This study has limitations. Although HHC stakeholders were recruited across 12 US states, other stakeholders were recruited from NY, and the modest sample may not be fully representative. Despite our efforts to recruit patients from under‐represented populations, the sample was predominantly non‐Hispanic White, and female, which may limit transferability, especially given unequal telehealth access and digital resources among those who could benefit most from telehealth‐enabled deprescribing. Telehealth definitions varied across stakeholders, reflecting real‐world practice but might have introduced heterogeneity. However, the use of retrospective self‐report may introduce recall bias. As an exploratory qualitative study, findings reflect stakeholder perspectives and should be interpreted accordingly. In conclusion, telehealth holds promise for supporting and goal‐concordant medication optimization and deprescribing during transitions from hospital to home. While not a universal solution, a hybrid model combining virtual prescriber consultations with in‐home clinician support could fill critical care gaps and enable patient‐centered, age‐friendly deprescribing. Author Contributions J.W. is responsible for study concept and design, acquisition of subjects and/or data, analysis and interpretation of data, preparation of manuscript, including the final version. J.Y.S. is responsible for study concept and design, acquisition of subjects and/or data, preparation of manuscript, and approval of the final version. F.Y. is responsible for the study concept and design, preparation of the manuscript, and approval of the final version. S.F.S. is responsible for study concept and design, preparation of manuscript, and approval of the final version. A.S.M. is responsible for study concept and design, preparation of manuscript, and approval of the final version. K.N. is responsible for study concept and design, analysis and interpretation of data, preparation of manuscript, and approval of the final version. M.S.M. is responsible for acquisition of subjects and/or data, analysis and interpretation of data, preparation of manuscript, including the final version. J.D.B. is responsible for acquisition of subjects and/or data, analysis and interpretation of data, preparation of manuscript, including the final version. S.A.N. is responsible for study concept and design, analysis and interpretation of data, preparation of manuscript, including the final version. K.L.H. is responsible for study concept and design, Sanalysis and interpretation of data, preparation of manuscript, including the final version. Y.J. is responsible for interpretation of data, preparation of manuscript, and approval of the final version. S.S. is responsible for interpretation of data, preparation of manuscript, and approval of the final version. N.P. is responsible for interpretation of data, preparation of manuscript, and approval of the final version. L.S. is responsible for interpretation of data, preparation of manuscript, and approval of the final version. J.A.Z. is responsible for interpretation of data, preparation of manuscript, and approval of the final version. C.L. is responsible for interpretation of data, preparation of manuscript, and approval of the final version. T.V.C. is responsible for study concept and design, acquisition of subjects and/or data, preparation of manuscript, and approval of the final version. All authors take accountability for all aspects of the work's integrity. Funding This study was conducted with the support of the following funders: National Institute on Aging (1K76AG083276‐01A1 [PI: J.W.]), U.S. Deprescribing Research Network (1R24AG064025 and R33AG086944; 2021‐2022 Pilot Award [Pilot PI: J.W.]) and the Alliance for Home Health Quality and Innovation, now called Research Institute for Home Care (J.W.: 2021 Home Health Care Research Funding). The views expressed in this article are those of the authors and do not necessarily represent the views of the funders. An abstract of this paper was submitted and presented at the 2025 MEDINFO conference in Taiwan. All authors meet the criteria for authorship stated in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals. Disclosure The sponsors had no role in study design, methods, subject recruitment, data collection, analyses, or interpretation of the paper. Conflicts of Interest The authors declare no conflicts of interest.